RU2223970C2 - Лечение ожирения - Google Patents

Лечение ожирения Download PDF

Info

Publication number
RU2223970C2
RU2223970C2 RU2000109265/04A RU2000109265A RU2223970C2 RU 2223970 C2 RU2223970 C2 RU 2223970C2 RU 2000109265/04 A RU2000109265/04 A RU 2000109265/04A RU 2000109265 A RU2000109265 A RU 2000109265A RU 2223970 C2 RU2223970 C2 RU 2223970C2
Authority
RU
Russia
Prior art keywords
peptide
cys
arg
val
gly
Prior art date
Application number
RU2000109265/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2000109265A (ru
Inventor
Франк Ман-Воон НГ (AU)
Франк Ман-Воон НГ
Воей-Дзиа ДЗИАНГ (AU)
Воей-Дзиа ДЗИАНГ
Original Assignee
Метаболик Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO9001A external-priority patent/AUPO900197A0/en
Priority claimed from AUPP0398A external-priority patent/AUPP039897A0/en
Application filed by Метаболик Фармасьютикалз Лтд. filed Critical Метаболик Фармасьютикалз Лтд.
Publication of RU2000109265A publication Critical patent/RU2000109265A/ru
Application granted granted Critical
Publication of RU2223970C2 publication Critical patent/RU2223970C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Percussion Or Vibration Massage (AREA)
RU2000109265/04A 1997-09-08 1998-09-04 Лечение ожирения RU2223970C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPO9001 1997-09-08
AUPO9001A AUPO900197A0 (en) 1997-09-08 1997-09-08 Treatment of obesity
AUPP0398A AUPP039897A0 (en) 1997-11-13 1997-11-13 Treatment of obesity
AUPP0398 1997-11-13

Publications (2)

Publication Number Publication Date
RU2000109265A RU2000109265A (ru) 2002-03-10
RU2223970C2 true RU2223970C2 (ru) 2004-02-20

Family

ID=25645599

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000109265/04A RU2223970C2 (ru) 1997-09-08 1998-09-04 Лечение ожирения

Country Status (12)

Country Link
US (2) US6737407B1 (enExample)
EP (1) EP1012189B1 (enExample)
JP (1) JP4334761B2 (enExample)
CN (1) CN1195776C (enExample)
AT (1) ATE377026T1 (enExample)
BR (1) BR9811755A (enExample)
CA (1) CA2303395C (enExample)
DE (1) DE69838647T2 (enExample)
ES (1) ES2296342T3 (enExample)
NZ (1) NZ502993A (enExample)
RU (1) RU2223970C2 (enExample)
WO (1) WO1999012969A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2450825C2 (ru) * 2005-02-23 2012-05-20 Университат Де-Лес-Ильес Балеарс Применение лептина для предотвращения избыточной массы тела и композиции, содержащие лептин

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
GB0315182D0 (en) * 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005007859A2 (en) * 2003-07-11 2005-01-27 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF ACETYL-COA CARBOXYLASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1755637B8 (en) * 2004-05-04 2012-10-03 Metabolic Pharmaceuticals Ltd. Methods for preventing or treating bone disorders
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20110092448A1 (en) * 2005-08-02 2011-04-21 Metabolic Pharmaceuticals Limited Peptide Conjugate for Oral Delivery of Hydrophilic Peptide Analgesics
WO2007068039A1 (en) * 2005-12-12 2007-06-21 Metabolic Pharmaceuticals Limited Treatment of weight gain in estrogen deficient mammals
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
WO2008098280A1 (en) * 2007-02-16 2008-08-21 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of dicarba bridges in growth hormone peptides
AU2009292651A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of AOD-like peptides
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
KR102148910B1 (ko) * 2011-12-09 2020-08-28 메타볼릭 파마슈티칼즈 피티와이 엘티디 성장 호르몬 단편들의 사용
CN102827290A (zh) * 2012-09-07 2012-12-19 浙江大学 人血清白蛋白与人生长激素脂肪分解结构域的融合蛋白
GB2507341A (en) * 2012-10-29 2014-04-30 Peter Kenny Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone
WO2019136528A1 (en) * 2018-01-15 2019-07-18 Lateral IP Pty Ltd Peptides and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (bg) 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4863901A (en) 1986-01-09 1989-09-05 Brigham & Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G.Y.W.Ma et al., Biochimica at Biophysica Acta, 1982, v.716, p. 400-409. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2450825C2 (ru) * 2005-02-23 2012-05-20 Университат Де-Лес-Ильес Балеарс Применение лептина для предотвращения избыточной массы тела и композиции, содержащие лептин

Also Published As

Publication number Publication date
DE69838647T2 (de) 2008-08-28
ES2296342T3 (es) 2008-04-16
EP1012189A4 (en) 2004-10-20
EP1012189A1 (en) 2000-06-28
WO1999012969A1 (en) 1999-03-18
JP4334761B2 (ja) 2009-09-30
DE69838647D1 (de) 2007-12-13
US6737407B1 (en) 2004-05-18
NZ502993A (en) 2002-12-20
BR9811755A (pt) 2000-08-29
CN1195776C (zh) 2005-04-06
JP2002501004A (ja) 2002-01-15
ATE377026T1 (de) 2007-11-15
US20040192608A1 (en) 2004-09-30
CN1275132A (zh) 2000-11-29
CA2303395C (en) 2008-12-02
EP1012189B1 (en) 2007-10-31
CA2303395A1 (en) 1999-03-18

Similar Documents

Publication Publication Date Title
US6320024B1 (en) Method for design of substances that enhance memory and improve the quality of life
JP4620309B2 (ja) 骨粗鬆症治療用副甲状腺ホルモン類似体
RU2000109265A (ru) Лечение ожирения
KR950702578A (ko) 파라티로이드 호르몬(pth) 및 파라티로이드 호르몬 관련 펩티드(pthrp)의 유사체, 이들의 합성 및 골다공증 치료를 위한 이들의 용도(analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis)
Chen et al. Structure–bioactivity of C‐terminal pentapeptide of osteogenic growth peptide [OGP (10–14)]
JP2002530430A (ja) Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物
KR960703015A (ko) 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS)
EP0828758A1 (en) Chimeric fatty body-pro-grf analogs with increased biological potency
CA2418793C (en) Pharmaceutical composition comprising an analgesic peptide
JP3621099B2 (ja) 骨原性成長オリゴペプチドおよびそれを含む医薬組成物
RU2157378C2 (ru) Полипептидные соединения, содержащие d-2-алкилтриптофан, стимулирующий высвобождение гормона роста
US6479460B1 (en) Synthetic peptides and pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same
AU2001280052A1 (en) Pharmaceutical composition comprising an analgesic peptide
KR900001719A (ko) 지질 및 폴리펩티드로 되는 합성 폐 계면활성제의 제조 방법
JP2000502089A (ja) 成長ホルモンの放出を促進できるｄ―２―アルキルトリプトファンを含有するオリゴペプチド化合物
RU2503684C2 (ru) Иммуномодулирующие олигопептиды
US20180215784A1 (en) Method for preparation of n-acyl peptides, polypeptides and proteins
KR950702574A (ko) 펩티드 폐 계면활성제 및 치료용 혼합물(Peptide Lung Surfactants and Therapeutic Combinations)
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения
Gagnon et al. D-LysAsnProTyr tetrapeptide: a novel B-cell stimulant and stabilized bursin mimetic
KR0141973B1 (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
JP2009502976A (ja) 親水性ペプチド鎮痛薬の経口送達のためのペプチドコンジュゲート
KR100630489B1 (ko) 면역반응을 조절하는 펩타이드
CA2008454A1 (en) Linear analog of biologically active mammalian grp or amphibian bombesin
PT87555B (pt) Processo para a preparacao e isolamento de esplenina humana e de composicoes farmaceuticas que a contem